Biocon: Improved Profitability Despite Weak Top-Line; Maintain BUY
We believe the company's valuations are at a comfortable level considering the its stable growth over a longer period. Therefore, we recommend BUY...
54 Views
Ramp-up in Biosimilars offset by lower Generic sales
BIOS delivered an operationally in line 2QFY22, while higher other income led the earnings beat. The healthy show in Research Services and ramp-up...
58 Views
Biocon: Steady Q2 Numbers Amid Better Margins
Robust biosimilar portfolio with partners like Viatris, Sandoz (for future launches), Adagio among others. Biosimilar US pipeline: (Approvals...
73 Views
Biocon: Price Erosion Impacts Growth in Biosimilars
Biocon reported weak numbers from the last 3 quarters, as the industry is facing price erosion challenges. Furthermore, the company is trading at...
136 Views
Biocon: Covid Related Challenges Drag Q1
Biocon is a leading biopharma company operating in biologics, small molecules, branded formulations and contract research.
109 Views